Exploring androgen receptor alterations (ARa) and their potential association with efficacy of first-line (1L) talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): A post hoc analysis of TALAPRO2 Free Meeting Abstract

cited authors

  • Liu, Glenn; Laird, A. Douglas; Agarwal, Neeraj; Zschabitz, Stefanie; Fizazi, Karim; Matsubara, Nobuaki; Joung, Jae Young; Karsh, Lawrence I.; Carles, Joan; Fay, Andre P.; Saul, Michelle; Mu, Xinmeng Jasmine; Yip, Steven M.; Childress, Merrida; Chelliserry, Jijumon; Healy, Cynthia G.; Wang, Fong; Kalac, Matko; Piulats, Josep M.; Azad, Arun A.

Publication Date

  • April 15, 2025

webpage

published in

category

volume

  • 85

issue

  • 8